Viekira Pak® (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) has been approved by the FDA and has now been added to the web, app and printed versions of the interactions charts. The combination is listed on the charts by its abbreviations – OBV/PTV/r + DSV. It is important to note that the current recommendations are based on the US Prescribing Information and the European SmPC will be referenced in the web site data base when it is available. It is important that where a recommendation given in an SmPC (e.g., Swiss) differs from the USPI that health care providers follow the relevant SmPC.
Viekira Pak® contains three new drugs—ombitasvir, paritaprevir and dasabuvir—that work together to inhibit the growth of HCV. It also contains ritonavir, a previously approved drug, which is used to increase blood levels of paritaprevir. Viekira Pak can be used with or without ribavirin, but it is not recommended for patients whose liver is unable to function properly (decompensated cirrhosis).
